Targeting FcRn for immunomodulation: Benefits, risks, and ... - PubMed
The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism to prevent degradation and extend the half-life of IgG and albumin in the circulation. Several …
The therapeutic age of the neonatal Fc receptor - Nature
2023年2月1日 · As such, FcRn blockade is a novel and effective strategy to reduce circulating levels of pathogenic IgG autoantibodies and curtail IgG-mediated diseases, with several FcRn …
Blocking FcRn in humans reduces circulating IgG levels and
Here, we report a humanized, affinity-matured IgG4-κ monoclonal antibody, SYNT001, that specifically interferes with human FcRn (hFcRn) binding to IgG and describe its …
FcRn inhibitors: a novel option for the treatment of myasthe ...
Several FcRn inhibitors have shown excellent efficacy and broad application prospects in MG-related studies. Indeed, one of these, efgartigimod, was approved by the United States Food …
Targeting FcRn for immunomodulation: Benefits, risks, and …
2020年9月1日 · The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism to prevent degradation and extend the half-life of IgG and albumin in the …
FcRn inhibitors have potential for future use in a much wider variety of antibody-mediated autoimmune diseases. Given the imminent clinical use, potential for broader utility, and novel …
FcRn: the neonatal Fc receptor comes of age - Nature
2007年8月17日 · FcRn is expressed in the epithelium of lungs and kidneys. IgG therapeutics delivered to the lungs can be absorbed via FcRn-mediated transcytosis. FcRn binds tightly to …
The efficacy and safety of FcRn inhibitors in patients with
2024年3月3日 · FcRn inhibitors have good efficacy and safety in patients with MG. Among them, efgartigimod and nipocalimab were effective without causing an increased safety risk. …
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
2024年4月22日 · To suppress the function of FcRn, which is beneficial to the treatment of IgG-driven autoimmune disorders like MG, CIDP, ITP, and stiff person syndrome. We review the …
The FcRn inhibitor rozanolixizumab reduces human serum IgG ... - PubMed
2017年11月1日 · Pathogenic immunoglobulin G (IgG) autoantibodies characterize some human autoimmune diseases; their high concentration and long half-life are dependent on recycling …